Skip to content
TrialScanner

NCT03589469

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2CompletedADCTLead

Registry record

Lead sponsor
ADC Therapeutics S.A.
Conditions
Diffuse Large B-Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent
Primary completion
May 24, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03589469 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03589469: Study to Evaluate the... | TrialScanner